Shanghai Cell Therapy Group, a leading player in the cell therapy industry in China, has announced the successful closing of its Series D1 financing, raising nearly RMB 500 million. The round was jointly invested by Jiuzhou Venture, Sun Rock Capital, and CCB International, with existing shareholder Haier Capital also participating. The funds from this round will be primarily used for product research and development, attracting key talents, and validating clinical results.

CEC Capital Group served as the exclusive financial advisor for Shanghai Cell Therapy Group in this transaction.

Shanghai Cell Therapy Group is a platform company in the Chinese immune cell industry, and is the first company worldwide to establish a closed-loop industry chain of "new drug technology research and development, tumor clinical treatment, and cell banking services." Founded in 2013, the company has been committed to using cell therapy technology to treat tumors and thereby improve the length and quality of life.